|
|
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Research Center of Pharmacology and Experimental Therapeutics, Department of Pharmacology (M.G., K.K., S.K., S.R., G.J., H.K.K.) and Department of Pharmacy (C.A.R.), Ernst Moritz Arndt University, Greifswald, Germany
Received May 8, 2006; accepted August 14, 2006
| Abstract |
|---|
|
|
|---|
To investigate the role of OATP2B1 in transport and supply of steroid hormone metabolites and precursors, we studied the effects of steroid hormones on OATP2B1 transport activity with regard to E3S and DHEAS uptake. In this article, we describe for the first time a stimulatory effect of progesterone on E3S and DHEAS uptake and characterize its kinetic parameters. Moreover, we identify pregnenolone sulfate as a new substrate for OATP2B1.
| Materials and Methods |
|---|
|
|
|---|
Radiolabeled substances were obtained as indicated in the respective section. All other substances used for transport studies were obtained from Sigma-Aldrich Chemie GmbH (Munich, Germany).
Cloning and Transfection. The full-length OATP2B1 cDNA was amplified using reverse-transcribed RNA from human placenta (forward primer, 5'-agctcactgcactccagcagtcatgg-3'; reverse primer, 5'-aaaggactcagaggaggtactgctgtggctgc-3') and cloned into the mammalian expression vector pcDNA3.1/hygro (Invitrogen, Carlsbad, CA). After verifying the sequence by cycle sequencing and matching against the reference sequence (accession number AB026256 [GenBank] .1), MDCKII cells were transfected with this construct using the FuGENE 6 Transfection Reagent (Roche, Penzberg, Germany). Cells were selected for antibiotic resistance using 0.6 mg/ml hygromycin B (Invitrogen).
Immunofluorescence Microscopy. Protein localization was investigated by confocal laser scanning immunofluorescence microscopy. For OATP2B1 a polyclonal antibody described before was used (rabbit, dilution 1:200) (Grube et al., 2005
). After washing with phosphate-buffered saline, the coverslides were incubated for 1 h with Alexa Fluor 488-labeled IgG (anti-rabbit IgG). Staining of nuclei was performed using a 1:2000 dilution of TOTO-3-iodide in DAKO Fluorescent Mounting Medium (Dako North America, Inc., Carpinteria, CA). The secondary antibodies as well as the TOTO dye were purchased from Invitrogen.
Immunoblot Analysis. Crude membrane fractions were loaded onto a 7.5% sodium dodecylsulfate-polyacrylamide gel after incubation in sample buffer at 95°C for 10 min. Immunoblotting was performed using a tank blotting system (Bio-Rad Laboratories, Hercules, CA) and an enhanced chemiluminescence detection system (GE Healthcare, Freiburg, Germany). The OATP2B1 primary antibody was diluted in Tris-buffered saline containing 0.05% Tween 20 and 5% bovine serum albumin. A secondary horseradish peroxidase-conjugated goat antirabbit antibody (BioRad) was used at a 1:2000 dilution.
Transport Studies. For characterization of OATP2B1 transfection, the respective cells were incubated with [3H]E3S (specific activity, 50 Ci/mmol) and [3H]DHEAS (specific activity, 60 Ci/mmol; both from Hartmann Analytic, Braunschweig, Germany) for 5 or 10 min, respectively, washed four times with ice-cold phosphate-buffered saline, and lysed with 0.2% SDS. An aliquot was mixed with 4 ml of scintillation cocktail (Rotiszint; Roth, Karlsruhe, Germany) and measured in a scintillation beta-counter (type 1409; PerkinElmer Wallac, Turku, Finland). For E3S uptake inhibition experiments as well as for transport studies with [3H]testosterone, [3H]progesterone, and [3H]pregnenolone sulfate (all 50 Ci/mmol; Biotrend, Köln, Germany), cells were seeded out in 24-well dishes, cultured to confluence, and incubated for indicated times with the respective substance at 37°C. Rates of transport are given in moles x milligrams of protein-1 x minutes-1 or as ratio of control. All transport studies were performed using an incubation buffer containing 140 mM NaCl2, 5mMKCl, 1mMKH2PO4, 1.2 mM MgSO4, 1.5 mM CaCl2, 5 mM glucose, and 12.5 mM HEPES, pH 7.3.
Statistical Methods. Values are represented as means ± S.D. Graphs and calculation were in general prepared using Excel (Microsoft Corp., Redmond, WA) or Prism software 3.0 (GraphPad Software, San Diego, CA) software. Student's t test was performed to determine statistical significance. Differences were considered significant at p < 0.05. The EC50 values were calculated by nonlinear regression from a sigmoidal dose-response curve (variable slope, bottom value
0) using GraphPad. Km and Vmax values were also calculated by nonlinear regression using the equation: Y = (Vmax·X)/(Km + X) by GraphPad.
| Results |
|---|
|
|
|---|
E3S and DHEAS Uptake Studies. As a first screening approach, OATP2B1-transfected cells were incubated with tritium-labeled E3S and DHEAS in the presence of various steroids. Substances such as estrone, estriol,
-estradiol, mifepristone, testosterone, and pregnenolone sulfate significantly inhibited E3S uptake. In contrast, steroids such as hydroxyprogesterone, pregnenolone, and progesterone enhanced the E3S uptake depending on their concentration (Table 1). For the uptake of DHEAS, similar results were observed; however, the inhibitory effects were less intense, whereas the inducing effects were much higher compared with the E3S results (Table 2). The inhibition/stimulation the compounds exerted on E3S uptake were similar to the effects on DHEAS transport. Interestingly, divergent results were obtained for estrone: E3S uptake was inhibited (68% of control for 100 µM E3S), whereas transport of DHEAS was induced up to 280% of control by estrone concentration of 10 and 100 µM (288 and 283%).
|
|
To further characterize the inhibitory effects of testosterone and mifepristone as well as the stimulatory effect of progesterone on E3S and DHEAS uptake mediated by OATP2B1, the concentration of the half-maximal effect (EC50) was determined. For the inhibition of testosterone, EC50 concentrations of 21.2 ± 5.1 µM for E3S and 15.4 ± 1.3 µM for DHEAS uptake were calculated; for mifepristone, the respective concentrations were 4.7 ± 0.7 µM for E3S and 2.2 ± 0.8 µM for DHEAS transport. The observed maximal inhibition of E3S and DHEAS uptake by testosterone and mifepristone was approximately 75% of control for both substances. In contrast, progesterone induces the uptake of E3S to a maximum of 200% and for DHEAS to 400% of control. These stimulatory effects show half-maximal concentrations of 1.5 ± 0.6 µM for E3S and 4.9 ± 1.5 µM for DHEAS (EC50 values are given as mean ± S.D. for three independent experiments). The maximal effects were obtained for a progesterone concentrations between 10 and 30 µM, whereas higher concentrations lead to decreased induction (Fig. 1).
|
|
Further experiments were carried out to investigate the stimulatory effect of progesterone on OATP2B1-mediated DHEAS uptake. OATP2B1-transfected cells were incubated with [3H]DHEAS and different progesterone concentrations in the presence of DMSO (0.1%) and 1 and 10 µM mifepristone (Fig. 2). The calculation of the EC50 revealed values of 2.8 ± 1.5 µM for the DMSO control, 5.3 ± 2.9 µM for 1 µM mifepristone, and 2.4 ± 0.4 µM for 10 µM mifepristone (EC50 values are given as mean ± S.D. for three independent experiments). However, the maximal induction effect decreases from 500% (control) to 144% in the presence of 10 µM mifepristone, indicating a noncompetitive interaction of progesterone and mifepristone.
|
|
OATP2B1 and Pregnenolone Sulfate. Pregnenolone sulfate (10 µM) significantly inhibited E3S and DHEAS transport to 28 and 43% of the control, respectively (Tables 1 and 2); moreover, an EC50 value of 3.5 ± 1.5 µM was calculated for E3S uptake (Fig. 4A). To determine whether pregnenolone sulfate is like other sulfates subject to OATP2B1-mediated transport, pregnenolone sulfate uptake experi-ments were performed in transfected and nontransfected cells. Incubation with pregnenolone sulfate revealed a time-dependent OATP2B1-mediated uptake. This transport was further stimulated by the addition of 10 µM progesterone, whereas progesterone had no effect on pregnenolone sulfate uptake into nontransfected cells (Fig. 4, B and C). To further characterize the stimulatory effect of progesterone on pregnenolone sulfate uptake, the concentration dependence was evaluated over a concentration range of 1.6 to 100 µM. Although progesterone had no effect on MDCKII cells, increasing concentrations of progesterone stimulated pregnenolone sulfate uptake with an EC50 value of 5.18 µM.
|
| Discussion |
|---|
|
|
|---|
In a first screening approach using an OATP2B1-overexpressing cell system, we were able to show significant inhibition of E3S and DHEAS uptake by steroid hormones or related compounds such as testosterone or mifepristone (Tables 1 and 2), whereas other steroids such as progesterone and pregnenolone demonstrated stimulatory effects on the uptake of both E3S and DHEAS. In the case of mifepristone and testosterone, the inhibitory effects were concentration-dependent with EC50 values of 4.7 µM (2.2 µM) and 21.2 µM (15.4 µM) for E3S (DHEAS), respectively. For both substrates used, the highest stimulatory effect of progesterone was observed for concentrations of around 10 µM, whereas higher progesterone concentrations were only slightly inductive or even inhibitory for DHEAS and E3S uptake. The mifepristone EC50 values are in the range of pharmacologically relevant levels (Sarkar, 2002
). In contrast, the EC50 values for progesterone and testosterone are very high compared with systemic concentrations [physiological progesterone concentration, 5-35 nM in women, depending on the menstrual cycle (Claydon et al., 2006
)]; however, serum concentrations might not reflect local conditions. This assumption is underlined by the observation of very high concentrations in the cord blood (mean concentration: 750 nM, ranging from 240 to 1670 nM) (Baik et al., 2005
) and the presence of elevated progesterone levels in nipple aspiration fluid of human breast (approximately 300 nM) (Khan et al., 2005
).
Although direct transport or inhibition by steroids or its metabolites have already been described for some uptake transport proteins of the OATP family, as well as ABC-efflux pumps such as P-glycoprotein (P-gp) or breast cancer resistance protein (Frohlich et al., 2004
; Pavek et al., 2005
; Konig et al., 2006
), observations of stimulatory steroid effects on uptake transport processes are rather rare. Pizzagalli et al. (2003
) described stimulatory effects of prostaglandin A1 on E3S uptake mediated by OATP2B1. It is also notable that the observed effects of progesterone and mifepristone on OATP2B1-mediated uptake of E3S and DHEAS are similar to their influence on the activity of the ABC transporter ABCB1 (P-glycoprotein, P-gp) (Fardel et al., 1996
; Shapiro et al., 1999
).
It is noteworthy that neither testosterone nor progesterone was transported by OATP2B1 for themselves (Table 3). Therefore, we hypothesized that testosterone blocks the E3S or DHEAS transport in a noncompetitive way. For progesterone, our observation excluded the possibility that the induction of E3S and DHEAS uptake is due to a progesterone-E3S-(DHEAS-) symport, which is underlined by the finding that no reciprocal stimulatory action of E3S or DHEAS on progesterone uptake was seen.
Further kinetic studies concerning the stimulatory effect of progesterone on E3S uptake led to the observation that progesterone increases the affinity of OATP2B1 toward E3S significantly (Fig. 3). Whether this effect is based on a direct modulatory interaction of progesterone with the substrate binding site of OATP2B1 or is due to an allosteric progesterone binding site as described by Shapiro et al. (1999
) for the interaction of progesterone and P-gp remains to be elucidated. The inhibitory action of high progesterone concentrations suggests the presence of two binding sites: one high-affinity allosteric binding site, which is responsible for the stimulatory effect and the substrate binding site, or a further allosteric binding site, toward which progesterone has lower affinity and an inhibitory effect.
Moreover, we were able to show that subinhibitory concentrations of the gestagene antagonist mifepristone (approximately 1 µM) were able to decrease the effect of progesterone on DHEAS uptake without altering the stimulatory EC50 concentrations of progesterone significantly, leading to the conclusion that mifepristone and progesterone are interacting in a noncompetitive way with OATP2B1 (Fig. 3). If mifepristone is thereby interacting directly with the DHEAS transport or is modulating a potential allosteric progesterone binding site remains to be elucidated. However, we assume that mifepristone has a higher affinity toward a potential allosteric progesterone binding site than progesterone. This assumption would explain our findings using low mifepristone concentrations and is supported by the fact that mifepristone acts in a similar way at the intracellular progesterone receptor.
Whereas DHEAS and E3S are already characterized as OATP2B1 substrates, pregnenolone sulfate, which represents a precursor molecule for gestagene synthesis (Chibbar and Mitchell, 1990
), is not described as an OATP2B1-substrate. However, our group and others demonstrated a strong inhibitory effect on E3S and DHEAS uptake (St-Pierre et al., 2002
). Moreover, in contrast to a previous study (Pizzagalli et al., 2003
), we observed a small but significant OATP2B1-dependent pregnenolone sulfate transport. This transport was enhanced by progesterone with an EC50 concentration for progesterone comparable with the above-mentioned values.
The presented findings are especially of interest with regard to the OATP2B1 expression in hormonally regulated tissues such as placenta or mammary gland (St-Pierre et al., 2002
; Pizzagalli et al., 2003
). The placenta, representing the main source of estrogens and progesterone during pregnancy, is unable to convert cholesterol into estrogen because of a lack of CYP17 and is therefore highly dependent on uptake of C-19 precursor steroids such as DHEAS (Voutilainen and Miller, 1986
). On the other hand, the placenta, or in more detail the syncytiotrophoblast, produces high levels of progesterone, which increases with the gestation age (Strauss et al., 1996
; Kallen, 2004
). In this context, the placental progesterone might be an important factor in regulation of DHEAS and E3S uptake. Moreover, our results also indicate a progesterone-enhanced uptake of pregnenolone sulfate via OATP2B1. This pathway represents a possible mechanism by which progesterone mediates the uptake of its own precursor molecules into the syncytiotrophoblast.
With respect to the mammary gland, circulating hormones (such as estrone-3-sulfate) and local biosynthesis within epithelial cells and stromal fibroblasts from precursors such as DHEAS and androstendione serve as estrogen-supplying mechanisms (Labrie et al., 2001
). The latter mechanism becomes increasingly important during aging because estrogen synthesis by the ovaries ceases completely during menopause (Labrie et al., 2003
). Similar to the placenta, the mammary gland is therefore also dependent on DHEAS and E3S uptake, and again OATP2B1 has been identified as the major uptake carrier. In contrast to the placenta, where the protein is localized to the basal membrane of the syncytiotrophoblast, here the localization is restricted to the myoepithelium, where it might play a role in the supply of desulfated hormones to the adjacent ductal epithelial cells (St-Pierre et al., 2002
; Pizzagalli et al., 2003
). Besides the general importance of OATP2B1 for the steroid metabolism in mammary gland, the stimulatory effect of progesterone on this transporter can be of relevance during pregnancy, when epithelial cells proliferate and milk-filled alveolar lobules develop in the mammary gland (Soyal et al., 2002
; Anderson and Clarke, 2004
).
Taken together, our data demonstrate strong interactions of OATP2B1-mediated uptake of E3S and DHEAS and steroid hormones. In the case of testosterone, transport of both substances was inhibited, whereas progesterone stimulated E3S and DHEAS uptake. These findings are of potential relevance for uptake regulation of sulfated steroid metabolites to sex steroid-responsive tissues such as liver, mammary gland, and placenta.
| Acknowledgements |
|---|
| Footnotes |
|---|
M.G. and K.K. contributed equally to this work.
ABBREVIATIONS: OATP, organic anionic polypeptide transporter; E3S, estrone-3-sulfate; DHEAS, dehydroepiandrosterone-sulfate; MDCK, Madin-Darby canine kidney; DMSO, dimethyl sulfoxide; P-gp, P-glycoprotein.
Address correspondence to: Dr. Heyo K. Kroemer, Department of Pharmacology, Friedrich-Loeffler-Str. 23d, 17487 Greifswald, Germany. E-mail: kroemer{at}uni-greifswald.de
| References |
|---|
|
|
|---|
Baik I, Devito WJ, Ballen K, Becker PS, Okulicz W, Liu Q, Delpapa E, Lagiou P, Sturgeon S, Trichopoulos D, et al. (2005) Association of fetal hormone levels with stem cell potential: evidence for early life roots of human cancer. Cancer Res 65: 358-363.
Baulieu EE (1996) Dehydroepiandrosterone (DHEA): a fountain of youth? J Clin Endocrinol Metab 81: 3147-3151.[CrossRef][Medline]
Baulieu EE and Robel P (1998) Dehydroepiandrosterone (DHEA) and dehydroepiandrosterone sulfate (DHEAS) as neuroactive neurosteroids. Proc Natl Acad Sci USA 95: 4089-4091.
Chibbar R and Mitchell BF (1990) Steroid sulfohydrolase in human chorion and decidua: studies using pregnenolone sulfate and dehydroepiandrosterone sulfate as substrate. J Clin Endocrinol Metab 70: 1693-1701.
Claydon VE, Younis NR, and Hainsworth R (2006) Phase of the menstrual cycle does not affect orthostatic tolerance in healthy women. Clin Auton Res 16: 98-104.[CrossRef][Medline]
Cui Y, Konig J, Leier I, Buchholz U, and Keppler D (2001) Hepatic uptake of bilirubin and its conjugates by the human organic anion transporter SLC21A6. J Biol Chem 276: 9626-9630.
Fardel O, Courtois A, Drenou B, Lamy T, Lecureur V, le Prise PY, and Fauchet R (1996) Inhibition of P-glycoprotein activity in human leukemic cells by mifepristone. Anticancer Drugs 7: 671-677.[CrossRef][Medline]
Frohlich M, Albermann N, Sauer A, Walter-Sack I, Haefeli WE, and Weiss J (2004) in vitro and ex vivo evidence for modulation of P-glycoprotein activity by progestins. Biochem Pharmacol 68: 2409-2416.[CrossRef][Medline]
Grube M, Schwabedissen HM, Draber K, Prager D, Moritz KU, Linnemann K, Fusch C, Jedlitschky G, and Kroemer HK (2005) Expression, localization, and function of the carnitine transporter octn2 (slc22a5) in human placenta. Drug Metab Dispos 33: 31-37.
Hagenbuch B and Meier PJ (2003) The superfamily of organic anion transporting polypeptides. Biochim Biophys Acta 1609: 1-18.[Medline]
Hagenbuch B and Meier PJ (2004) Organic anion transporting polypeptides of the OATP/SLC21 family: phylogenetic classification as OATP/SLCO superfamily, new nomenclature and molecular/functional properties. Pflueg Arch Eur J Physiol 447: 653-665.[CrossRef][Medline]
Kallen CB (2004) Steroid hormone synthesis in pregnancy. Obstet Gynecol Clin North Am 31: 795-816.[CrossRef][Medline]
Khan SA, Bhandare D, and Chatterton RT Jr (2005) The local hormonal environment and related biomarkers in the normal breast. Endocr Relat Cancer 12: 497-510.
Kobayashi D, Nozawa T, Imai K, Nezu J, Tsuji A, and Tamai I (2003) Involvement of human organic anion transporting polypeptide OATP-B (SLC21A9) in pH-dependent transport across intestinal apical membrane. J Pharmacol Exp Ther 306: 703-708.
Konig J, Cui Y, Nies AT, and Keppler D (2000a) A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane. Am J Physiol 278: G156-G164.
Konig J, Cui Y, Nies AT, and Keppler D (2000b) Localization and genomic organization of a new hepatocellular organic anion transporting polypeptide. J Biol Chem 275: 23161-23168.
Konig J, Seithel A, Gradhand U, and Fromm MF (2006) Pharmacogenomics of human OATP transporters. Naunyn-Schmiedeberg's Arch Pharmacol 372: 432-443.[CrossRef][Medline]
Kullak-Ublick GA, Fisch T, Oswald M, Hagenbuch B, Meier PJ, Beuers U, and Paumgartner G (1998) Dehydroepiandrosterone sulfate (DHEAS): identification of a carrier protein in human liver and brain. FEBS Lett 424: 173-176.[CrossRef][Medline]
Kullak-Ublick GA, Ismair MG, Stieger B, Landmann L, Huber R, Pizzagalli F, Fattinger K, Meier PJ, and Hagenbuch B (2001) Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology 120: 525-533.[CrossRef][Medline]
Labrie F, Luu-The V, Labrie C, Belanger A, Simard J, Lin SX, and Pelletier G (2003) Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. Endocr Rev 24: 152-182.
Labrie F, Luu-The V, Labrie C, and Simard J (2001) DHEA and its transformation into androgens and estrogens in peripheral target tissues: intracrinology. Front Neuroendocrinol 22: 185-212.[CrossRef][Medline]
Miki Y, Nakata T, Suzuki T, Darnel AD, Moriya T, Kaneko C, Hidaka K, Shiotsu Y, Kusaka H, and Sasano H (2002) Systemic distribution of steroid sulfatase and estrogen sulfotransferase in human adult and fetal tissues. J Clin Endocrinol Metab 87: 5760-5768.
Pavek P, Merino G, Wagenaar E, Bolscher E, Novotna M, Jonker JW, and Schinkel AH (2005) Human breast cancer resistance protein: interactions with steroid drugs, hormones, the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine, and transport of cimetidine. J Pharmacol Exp Ther 312: 144-152.
Pizzagalli F, Varga Z, Huber RD, Folkers G, Meier PJ, and St-Pierre MV (2003) Identification of steroid sulfate transport processes in the human mammary gland. J Clin Endocrinol Metab 88: 3902-3912.
Santner SJ, Leszczynski D, Wright C, Manni A, Feil PD, and Santen RJ (1986) Estrone sulfate: a potential source of estradiol in human breast cancer tissues. Breast Cancer Res Treat 7: 35-44.[CrossRef][Medline]
Sarkar NN (2002) Mifepristone: bioavailability, pharmacokinetics and useeffectiveness. Eur J Obstet Gynecol Reprod Biol 101: 113-120.[CrossRef][Medline]
Satoh H, Yamashita F, Tsujimoto M, Murakami H, Koyabu N, Ohtani H, and Sawada Y (2005) Citrus juices inhibit the function of human organic aniontransporting polypeptide OATP-B. Drug Metab Dispos 33: 518-523.
Shapiro AB, Fox K, Lam P, and Ling V (1999) Stimulation of P-glycoproteinmediated drug transport by prazosin and progesterone. Evidence for a third drug-binding site. Eur J Biochem 259: 841-850.[Medline]
Skalba P, Wojtowicz M, and Sikora J (2003) Androgen and SHBG serum concentrations in late post-menopause women. Med Sci Monit 9: CR152-CR156.[Medline]
Soyal S, Ismail PM, Li J, Mulac-Jericevic B, Conneely OM, and Lydon JP (2002) Progesterone's role in mammary gland development and tumorigenesis as disclosed by experimental mouse genetics. Breast Cancer Res 4: 191-196.[CrossRef][Medline]
St-Pierre MV, Hagenbuch B, Ugele B, Meier PJ, and Stallmach T (2002) Characterization of an organic anion-transporting polypeptide (OATP-B) in human placenta. J Clin Endocrinol Metab 87: 1856-1863.
Strauss JF 3rd, Martinez F, and Kiriakidou M (1996) Placental steroid hormone synthesis: unique features and unanswered questions. Biol Reprod 54: 303-311.[Abstract]
Tamai I, Nezu J, Uchino H, Sai Y, Oku A, Shimane M, and Tsuji A (2000) Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem Biophys Res Commun 273: 251-260.[CrossRef][Medline]
Tamai I, Nozawa T, Koshida M, Nezu J, Sai Y, and Tsuji A (2001) Functional characterization of human organic anion transporting polypeptide B (OATP-B) in comparison with liver-specific OATP-C. Pharm Res (NY) 18: 1262-1269.
Ugele B, St-Pierre MV, Pihusch M, Bahn A, and Hantschmann P (2003) Characterization and identification of steroid sulfate transporters of human placenta. Am J Physiol 284: E390-E398.
Voutilainen R and Miller WL (1986) Developmental expression of genes for the stereoidogenic enzymes P450scc (20,22-desmolase), P450c17 (17 alphahydroxylase/17,20-lyase), and P450c21 (21-hydroxylase) in the human fetus. J Clin Endocrinol Metab 63: 1145-1150.
This article has been cited by other articles:
![]() |
T. Nishimura, Y. Seki, K. Sato, T. Chishu, N. Kose, T. Terasaki, Y.-S. Kang, Y. Sai, and E. Nakashima Enhancement of Zidovudine Uptake by Dehydroepiandrosterone Sulfate in Rat Syncytiotrophoblast Cell Line TR-TBT 18d-1 Drug Metab. Dispos., October 1, 2008; 36(10): 2080 - 2085. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||